← Human Trials & Peer-Reviewed Studies
Methylene blue intra-arterial staining of resected colorectal cancer specimens improves accuracy of nodal staging: A randomized controlled trial
Plain-language guide to PMID 27462023 (2016): randomized controlled trial study of Methylene blue (non-peptide stack partner).
Key Facts
- PMID
- 27462023
- Journal
- European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology
- Year
- 2016
- Study type
- Randomized Controlled Trial
- Authors
- Reima H et al. (4 authors)
- DOI
- 10.1016/j.ejso.2016.06.001
What This Study Did, in Plain Language
What Was Tested
This randomized controlled trial paper looks at Methylene blue (non-peptide stack partner).
The aim of the study was to assess the effect of intra-arterial staining of colorectal specimens with methylene blue on lymph node harvest.
Why It Was Studied
Metastatic involvement of regional lymph nodes is a major prognostic factor of colorectal cancer, which influences also its treatment strategy.
International consensus foresees retrieval of ≥12 lymph nodes from colorectal specimens.
Who Took Part
By PubMed's age tags, the people studied were adults, middle-aged adults, older adults and people over 80, both men and women.
A total of 266 radically operated colorectal cancer patients were randomized into the methylene blue staining and non-staining groups.
In the staining group, methylene blue solution was injected into the colorectal specimen's artery after its removal.
How the Study Was Run
The design is described as randomized.
Because people in this Methylene blue (non-peptide stack partner) study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.
The specimens were analysed for lymph node count, diameter and metastatic involvement.
What Was Measured
Topics PubMed links to this paper include Colorectal Neoplasms, Lymph Nodes, Methylene Blue, Neoplasm Staging and Staining and Labeling.
Author keywords: Colon cancer, Colorectal cancer and Rectal cancer.
What This Means in Plain Language
The paper is a randomized study of Methylene blue (non-peptide stack partner).
Results are reported in around 7 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2016 (European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology), a journal based in England.
More context: the Methylene blue (non-peptide stack partner) compound page, all human trials.
Our Notes on the Compound
Methylene blue (non-peptide stack partner): Described as an electron cycler, not just a dye.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.